NEULANDLAB · Healthcare
Neuland Laboratories Ltd. reported revenue of ₹393 cr for October to December 2023, — on the year and −6.0% on the quarter.
Operating profit (EBITDA) was ₹121 cr, a margin of 30.8%, — on the year and −199 bps on the quarter.
Net profit was ₹81.0 cr, — on the year and −9.0% on the quarter, with earnings per share of ₹63.44.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Headline vs core profit, Exceptional items that recur, Operating margin on the year, Depreciation falling, Finance cost rising, Swing to loss or profit, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹418 cr | ₹393 cr | ₹385 cr | ₹440 cr | ₹311 cr | ₹398 cr | ₹328 cr | ₹293 cr | ₹514 cr | ₹440 cr | ₹776 cr | ₹642 cr |
| YoY | — | — | — | +21% | −26% | +1% | −15% | −33% | +65% | +11% | +137% | +119% |
| EBITDA margin | 32.8% | 30.8% | 27.8% | 28.0% | 19.9% | 21.9% | 15.5% | 11.6% | 30.4% | 17.5% | 39.6% | 34.7% |
| Other income, % of PBT | 2% | 2% | 5% | 19% | 8% | 47% | 18% | 44% | 2% | 15% | 4% | 4% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 27% | 22% | 27% | 25% | 34% | 20% | 29% | 21% | 25% | 26% | 26% | 25% |
| Net profit | ₹89.0 cr | ₹81.0 cr | ₹68.0 cr | ₹98.0 cr | ₹33.0 cr | ₹102 cr | ₹28.0 cr | ₹14.0 cr | ₹97.0 cr | ₹41.0 cr | ₹213 cr | ₹148 cr |
| YoY | — | — | — | +58% | −63% | +26% | −59% | −86% | +194% | −60% | +661% | +957% |
| Core profit YoY | — | — | — | +30% | −62% | −33% | −63% | −90% | +182% | −32% | +759% | +1,800% |
| EPS | ₹69.56 | ₹63.44 | ₹52.66 | ₹76.28 | ₹25.60 | ₹79.18 | ₹21.68 | ₹10.83 | ₹75.49 | ₹31.62 | ₹165.76 | ₹115.10 |
| Flags | · | · | · | 1 | 1 | 3 | 1 | 2 | ✓ | 1 | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Neuland Laboratories Ltd. reported revenue of ₹393 cr (— on the year) and net profit of ₹81.0 cr (— on the year) for October to December 2023.
None of the 2 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.